Capital Research Global Investors Boosts Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Capital Research Global Investors raised its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 32.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,968,513 shares of the biopharmaceutical company’s stock after buying an additional 1,724,610 shares during the quarter. Capital Research Global Investors owned about 0.05% of Alnylam Pharmaceuticals worth $1,639,767,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ALNY. Regeneron Pharmaceuticals Inc. acquired a new position in Alnylam Pharmaceuticals during the fourth quarter worth $1,045,822,000. Norges Bank purchased a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $577,941,000. Marshall Wace LLP grew its position in Alnylam Pharmaceuticals by 496.6% in the 4th quarter. Marshall Wace LLP now owns 378,649 shares of the biopharmaceutical company’s stock valued at $89,100,000 after acquiring an additional 315,182 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter worth about $65,295,000. Finally, Jennison Associates LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $61,160,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CMO Pushkal Garg sold 1,548 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $251.67, for a total transaction of $389,585.16. Following the transaction, the chief marketing officer now directly owns 11,989 shares in the company, valued at approximately $3,017,271.63. This represents a 11.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total transaction of $362,246.40. Following the transaction, the executive vice president now directly owns 12,881 shares of the company’s stock, valued at approximately $3,240,344.36. This represents a 10.06 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 71,234 shares of company stock worth $19,958,097. Insiders own 1.50% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on ALNY shares. Royal Bank of Canada lifted their price objective on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an “outperform” rating in a report on Friday, March 21st. Needham & Company LLC reaffirmed a “buy” rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 9th. Citigroup increased their price objective on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a “buy” rating in a research note on Friday, March 21st. StockNews.com cut Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, March 21st. Finally, Canaccord Genuity Group increased their price target on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a “buy” rating in a research report on Friday, March 21st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $315.58.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ:ALNY opened at $234.56 on Friday. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The stock has a market capitalization of $30.51 billion, a price-to-earnings ratio of -108.09 and a beta of 0.30. The company has a 50-day simple moving average of $249.14 and a 200-day simple moving average of $257.07. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.